help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chow, C. C.
Right arrow Articles by Cockram, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chow, C. C.
Right arrow Articles by Cockram, C. S.
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 2 581-587
Copyright © 2003 by The Endocrine Society

Oral Alendronate Increases Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism

C. C. Chow, W. B. Chan, June K. Y. Li, Norman N. Chan, Michael H. M. Chan, Gary T. C. Ko, K. W. Lo and Clive S. Cockram

Departments of Medicine and Therapeutics (C.C.C., W.B.C., N.N.C., C.S.C.) and Chemical Pathology (M.H.M.C.), The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong; Department of Medicine, Yan Chai Hospital, Hong Kong (J.K.Y.L.); Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong (G.T.C.K.); and Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong (K.W.L.)

Address all correspondence and requests for reprints to: Dr. C. C. Chow, Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. E-mail: ccf193chow{at}cuhk.edu.hk.


   Abstract
Top
 Abstract
Introduction
 Patients and Methods
 Results
 Discussion
 References
 
The effect of biphosphonate therapy on bone mineral density (BMD) in patients with primary hyperparathyroidism (PHP) is unknown. Forty postmenopausal women (mean age, 70 yr) with PHP were randomized to receive alendronate 10 mg/d or placebo for 48 wk, followed by treatment withdrawal for 24 wk. The mean (±SD) changes in BMD at femoral neck (+4.17 ± 6.01% vs. -0.25 ± 3.3%; P = 0.011) and lumbar spine (+3.79 ± 4.04% vs. 0.19 ± 2.80%; P = 0.016) were significantly higher with alendronate at 48 wk. Serum calcium was reduced with alendronate but not placebo (-0.09 vs. +0.01 mmol/liter; P = 0.018). Serum bone-specific alkaline phosphatase activity was lower with alendronate from 12 wk onward and increased 24 wk after treatment withdrawal (21.1 ± 12.8 to 7.3 ± 4.9 IU/liter at 48 wk, and 15.0 ± 14.8 IU/liter 24 wk after withdrawal; P = 0.002 for trend). Osteocalcin concentration decreased at 48 wk and increased 24 wk after alendronate withdrawal (P = 0.019 for trend of change over time) but not with placebo. Urinary N-telopeptide/creatinine ratio decreased with alendronate at 48 wk and increased 24 wk after treatment withdrawal (P = 0.008 for trend). N-telopeptide/creatinine ratio did not change with placebo. Alendronate improves BMD and reduces bone turnover markers in postmenopausal women with PHP.


   Introduction
Top
 Abstract
 Introduction
Patients and Methods
 Results
 Discussion
 References
 
PRIMARY HYPERPARATHYROIDISM (PHP) is common, with an incidence estimated to be 277 per million in Western populations and a higher prevalence in postmenopausal women (1). It has been increasingly diagnosed since the introduction of routine multichannel autoanalyzer measurement of serum calcium in the 1970s (2). Previously, the disease had been characterized by the symptoms of frank hypercalcemia, renal calculi, and parathyroid bone disease (3). For decades, the definitive treatment has been surgical resection. Nowadays, approximately 80% of patients are asymptomatic and present as an incidental finding (4). Furthermore, a large proportion of these patients is elderly, with multiple medical problems, and carries a definite surgical risk (5). The management of such patients remains controversial, even with the introduction of National Institutes of Health (NIH) guidelines, and the adherence to guidelines has also been shown to be poor (6).

Despite largely asymptomatic presentation, the skeleton remains a target organ of concern in the hyperparathyroid disease process. Classically, effects of excess PTH on bone are seen with preferential involvement of the cortical sites, such as the distal forearm, and relative sparing of the cancellous sites, such as the lumber spine (7). The underlying pathophysiology is probably due to increased bone turnover with enhancement in both bone resorption and bone formation (8). An increase in bone mineral density (BMD) has also been observed in patients after parathyroidectomy (9). Paradoxically, the greatest increments have been reported to occur in the cancellous bone, with a 10% increase in lumber spine BMD and a 14% increase in femoral neck BMD after 10 yr, respectively (9). Medical therapy for PHP using sex hormone replacement has previously shown preservation of BMD in postmenopausal women (10, 11). However, compliance with long-term sex hormone replacement has been shown to be poor (12).

Bisphosphonates are analogs of inorganic pyrophosphate that inhibit bone resorption, the driving force of increased bone turnover in patients with PHP (13). Bisphosphonates have been shown to be safe and effective in the treatment of postmenopausal and glucocorticoid-induced osteoporosis (14, 15, 16). Intravenous pamidronate acutely has been shown to be effective in lowering serum calcium in PHP for at least 1–2 wk (17, 18). Several oral bisphosphonates have been used to treat PHP up to 12 wk. These short-term small studies have demonstrated slight reduction of serum calcium, together with decrease in serum alkaline phosphatase activity and urine hydroxyproline, indicating that bone turnover is reduced (19, 20, 21). However, a compensatory rise in the level of PTH may occur, which may limit the use of oral bisphosphonates in PHP (18, 20). There are very limited data available concerning the efficacy and safety of longer duration of bisphosphonate use in patients with PHP. In this double-blind, randomized, placebo-controlled trial, we examined the efficacy of oral alendronate, a potent second-generation bisphosphonate, in the management of postmenopausal women with PHP over a period of 48 wk, with further follow-up of 24 wk after discontinuation of therapy.


   Patients and Methods
Top
 Abstract
 Introduction
 Patients and Methods
Results
 Discussion
 References
 
Patients

This is a double-blind, randomized, placebo-controlled trial. Forty postmenopausal women with PHP were recruited. The BMD at femoral neck was chosen as the primary endpoint. Secondary endpoints included BMD at lumber spine and distal radius and serum albumin-adjusted calcium concentration.

PHP was diagnosed by a trained endocrinologist based on a serum albumin-adjusted calcium concentration greater than 2.62 mmol/liter (normal range, 2.15–2.55 mmol/liter) with an inappropriately normal or raised serum PTH concentration. The patients who were recruited were grouped as follows: 1) those who did not reach criteria for surgery according to the NIH guideline (22); 2) those who preferred not to have surgery; 3) those who were considered to be at too high surgical risk; and 4) those who were on the waiting list for surgery. Three had a history of previous fracture. One had fractured neck of the femur, and two had collapsed lumbar spine. All had spinal anatomy suitable for dual-energy x-ray densitometry measurement at three vertebrae from L1–L4 at least. We excluded patients who received bisphosphonates, calcitonin, gallium nitrate, mithramycin, or fluoride treatment within 1 yr of recruitment. We also excluded patients on sex hormone replacement therapy (HRT) and patients who were taking medications that will affect bone metabolism, including steroid, anticonvulsants, vitamin D in excess of 1,000 U/d, and vitamin A in excess of 10,000 U/d. Patients who had underlying diseases that may affect bone metabolism were also excluded. These included Paget’s disease, osteogenesis imperfecta, rheumatoid arthritis, systemic lupus erythematosus, and other collagen vascular diseases. We excluded patients with unstable angina or myocardial infarction within 1 yr before study entry, patients with malignancy within the past 10 yr, patients with significant renal impairment defined as serum creatinine greater than 150 µmol/liter, or other end organ damage that might pose risk or complicate participation in the study. All patients provided written consent, and the study protocol were approved by the University Ethical Committee.

Study design

At the first visit, a full clinical assessment and physical examination were performed. These included demographic data and symptoms of PHP. Fasting blood samples were taken at screening for measurement of serum concentrations of calcium, phosphate, albumin, total alkaline phosphatase activity, and TSH. Patients were seen 4 wk later as wk 0, and were randomized in 1:1 ratio to have either alendronate 10 mg/d or placebo for 48 wk if they fulfilled all inclusion and exclusion criteria. All patients were instructed to take the study drug each morning while fasting, at least 30 min before the first meal, with at least 125 ml of plain water. They were instructed to remain upright for at least 30 min after taking the drug. Throughout the study, the patients were instructed on normal calcium diet and avoiding extra vitamin D supplement. The patients attended for follow-up at wk 4, 12, 24, 36, and 48. At each visit, patients were asked to bring back the remaining test drugs for estimation of compliance by tablet counting. They were also questioned about symptoms of PHP using a standardized questionnaire that included symptoms of bone, joint, gastrointestinal tract, and general well-being. Questions about adverse events other than the above-mentioned aspects were asked in an open fashion manner. Fasting blood samples were taken for measurement of serum concentrations of albumin, calcium, phosphate, osteocalcin, PTH, 25-hydroxyvitamin D, and bone-specific alkaline phosphatase activity (Bone-ALP). Samples of 24-h urine were collected for measurement of daily urinary calcium excretion and concentrations of creatinine and urinary N-telopeptide.

BMD was measured at wk 0, 24, and 48 using dual-density x-ray absorptiometry (model QDR-2000 bone densitometer, Hologic, Inc. Waltham, MA.). Measurements were taken at femoral neck, lumbar spine (L2, L3, and L4), and distal third of the nondominant radius. Vertebrae with deformities and focal sclerosis were excluded from measurement. The CV of these measurements on a phantom spine was 0.4%. After wk 48, the test drug was stopped. The patients were then reassessed at wk 60 and 72. Blood was again taken at these two visits for serum concentrations of albumin, calcium, phosphate, Bone-ALP, and PTH. BMD was measured again at wk 72.

Methods

All blood samples were centrifuged and sera aliquoted immediately after collection. They were deep-frozen at -70 C together with all urine samples until analysis in one single batch. Serum PTH was measured using a two-site sandwich-type chemiluminometric assay (Immulite, Diagnostic Products Corp., Los Angeles, CA) that only detects the intact PTH molecule. The lower limit of detection of the assay was 0.1 pmol/liter, and the assay was capable of detecting PTH in all normal subjects. The interassay CV was 8.6% at 6.2 pmol/liter. Serum total calcium was measured by bichromatic endpoint technique after reacting with o-cresolphthalein (Dimension AR, Dade Behring Inc., Newark, DE). The values were then adjusted with serum albumin concentration using the following formula: Adjusted calcium (in mmol/liter) = Measured calcium (in mmol/liter) + 0.025 x [40 - Measured albumin (in g/liter)] (Ref. 23). Urinary calcium concentration was measured using the bichromatic endpoint technique after reacting with o-cresolphthalein I alkaline solution (Hitachi 911, Roche Diagnostics Corp., Indianapolis, IN). Serum 25-hydroxyvitamin D was measured using a competitive protein-binding assay after extraction (125I RIA kit, DiaSorin, Inc., Stillwater, MN). The interassay CV was 9.4% at 8.6 µg/liter. Bone-ALP was quantified by precipitation with wheat-germ lectin. Osteocalcin (Diagnostic Systems Laboratories Inc., Webster, TX) and urine N-telopeptide (Ostex International, Inc., Seattle, WA) were measured by two-site, sandwich-type, enzyme-linked immunosorbent assay. Urine creatinine (Roche Diagnostics Corp.) concentrations were measured by chemiluminescence immunoassay and kinetic Jaffe reaction. The interassay CV for osteocalcin, Bone-ALP, N-telopeptide, and creatinine measurements were 5.6% at 1.2 µg/liter, 1.8% at 394 IU/liter, 9.2% at 402 nmol/liter, and 2.8% at 8.51 mmol/liter, respectively.

Statistical analysis

The data were analyzed using SPSS 8.0 for Windows (SPSS, Inc., Chicago, IL). The data are expressed in mean ± SD. BMD is expressed as grams per square centimeter, and change in BMD is expressed as percentage change. Baseline data were compared using an unpaired t test. Changes in BMD at 48 wk between two groups were compared using an unpaired t test. Changes in BMD at femoral neck were the prespecified primary endpoint, whereas P values of all other secondary endpoints were adjusted for multiple comparisons (24). Serial changes of serum calcium, phosphate, Bone-ALP, and BMD were analyzed exploratory with ANOVA of repeated measures, with treatment group as the independent variable. We used the Bonferroni method for multiple adjustment. Changes in symptomatology between groups were compared using a {chi}2 test. Our previous study has shown that the SD of change in BMD at femoral neck was around 3% (our unpublished data). The present study has 90% power to detect a 3% difference in BMD at femoral neck between the two groups.


   Results
Top
 Abstract
 Introduction
 Patients and Methods
 Results
Discussion
 References
 
Characteristics of the patients

Forty patients were screened; all were eligible and agreed to participate in the study. The mean (±SD) age of the patients was 70 ± 9.3 yr, with a mean known duration of disease of 1.8 ± 1.4 yr. Only 2.5% had a raised serum Bone-ALP, 30% of the patients had a history of renal calculi, and 12.5% had a history of peptic ulcer or upper gastrointestinal bleeding. The whole group had a high prevalence of concomitant medical illnesses: 65% with hypertension, 32.5% with diabetes mellitus, and 17.5% with ischemic heart disease. There was no significant difference in the clinical characteristics between the two groups (Table 1Go).


View this table:
[in this window]
[in a new window]
  		Table 1. Demographic and clinical characteristics of the patients

 
Thirty-six patients completed the study. One patient in the alendronate group withdrew due to anxiety about the test drug after discussion with family members. Three patients withdrew in the placebo group. One had ß-blocker-induced heart block, one developed ibuprofen-induced gastric ulcer, and one could not comply with the protocol because of poor mobility due to Parkinsonism. The overall drug compliance was 90%.

BMD

The patients were generally osteoporotic with baseline BMD 0.540 ± 0.112 g/cm2 (T score, -2.07 ± 1.04) at femoral neck, 0.712 ± 0.132 g/cm2 (T score, -2.54 ± 1.25) at lumbar spine, and 0.478 ± 0.086 g/cm2 (T score, -3.58 ± 1.43) at distal third of radius (Table 1Go). BMD at the distal radius could not be measured in seven subjects because they were unable to either remain still during scanning or remove a jade bracelet from the wrist. There was no significant difference between the two groups.

At 48 wk, the change in BMD at the femoral neck was statistically different between the two groups (+4.17 ± 6.01% for alendronate vs. -0.25 ± 3.35% for placebo; P = 0.011). BMD in the alendronate group subsequently fell to +3.42 ± 6.29% 24 wk after withdrawal of treatment (P = 0.012 for trend of change over time). The BMD of the placebo group did not show significant changes throughout the study period (P = 0.291). The difference in trend between the two groups was statistically significant (P = 0.005; Fig. 1Go).



View larger version (14K):
[in this window]
[in a new window]
  		Figure 1. Mean (±SE) changes in BMD from baseline-line values in postmenopausal women with PHP receiving alendronate or placebo over 48 wk. Data are shown for BMD (measured by dual energy x-ray absorptiometry) at the femoral neck, spine, and distal forearm. Treatment was withdrawn at wk 48. *, P < 0.05 between two groups.

 
At 48 wk, the change in BMD at the lumbar spine was also significantly different between the two groups (+3.79 ± 4.04% for alendronate vs. +0.19 ± 2.80% for placebo; P = 0.016). In the alendronate group, the BMD at the lumbar spine subsequently fell to +2.41 ± 4.60% at 24 wk after withdrawal of treatment (P = 0.004 for trend of change over time). The BMD in the placebo group showed no significant change throughout the study (P = 0.073; Fig. 1Go). There was no difference in change of BMD at the distal third of radius at 48 wk (+1.01 ± 2.32% vs. 0.07 ± 5.50%; P = 0.573) between the two groups (Fig. 1Go).

Calcium and biochemical markers of bone turnover

The change in serum calcium concentration was significantly different between the two groups (-0.09 for alendronate vs. +0.01 mmol/liter for placebo; P = 0.036). In the alendronate group, serum calcium concentration showed significant decrease from a mean of 2.82 mmol/liter at baseline to 2.74 mmol/liter at the end of 48 wk and rose to 2.78 mmol/liter 24 wk after drug withdrawal (P = 0.003 for trend of change over time). Serum calcium did not show significant change in the placebo group (P = 0.484). The trend in change of calcium showed significant difference between the two groups (P = 0.028; Fig. 2Go). There was no significant change in serum phosphate in either group (data not shown). The change in serum PTH was not significantly different at 48 wk (P = 0.110), and the trend of changes was not significantly different between the two groups (P = 0.110; Fig. 2Go). Eight of the 40 subjects had a 25-hydroxyvitamin D concentration less than 10 ng/liter, suggesting underlying vitamin D deficiency. However, there was no significant difference in serum calcium concentration between the vitamin D-deficient subjects and the vitamin D-sufficient subjects (2.76 vs. 2.83 mmol/liter; P = 0.301).



View larger version (19K):
[in this window]
[in a new window]
  		Figure 2. Serum calcium and PTH level (mean ± SE) in postmenopausal women with PHP receiving alendronate or placebo over 48 wk. Serum calcium was albumin adjusted. Change in serum calcium was significantly different (P = 0.036), whereas change in PTH was not significantly different (P = 0.110) at 48 wk.

 
In the alendronate group, serum Bone-ALP followed a trend of change opposite to that of BMD with a progressive decrease from 21.1 ± 12.8 IU/liter to 7.3 ± 4.9 IU/liter (P < 0.001) at the end of 48 wk of treatment. Bone-ALP then rose again to 15.0 ± 14.8 IU/liter (P = 0.088) 24 wk after withdrawal of treatment (P = 0.002 for trend of change over time). In the placebo group, Bone-ALP did not change significantly during the study. The difference in trend between the two groups was statistically significant (P = 0.007; Fig. 3Go).



View larger version (23K):
[in this window]
[in a new window]
  		Figure 3. Serum Bone-ALP, osteocalcin, urinary N-telopeptide/creatinine ratio and 24-h urinary calcium excretion (mean ± SE) in postmenopausal women with PHP receiving alendronate or placebo over 48 wk.

 
Other bone formation and resorption markers, as well as changes in serum osteocalcin concentration, showed a similar trend. In the alendronate group, serum osteocalcin concentration decreased from a baseline value of 53.0 ± 28.9 µg/liter to 26.5 ± 14.8 µg/liter (P < 0.001) at 48 wk and rose to 36.6 ± 24.6 µg/liter (P = 0.019) 24 wk after withdrawal of treatment (P = 0.019 for trend of change over time). In the placebo group, serum osteocalcin concentration did not change throughout the study. The difference in trend between the two groups was again statistically significant (P = 0.004; Fig. 3Go).

In the alendronate group, urinary N-telopeptide/creatinine ratio showed a significant drop from baseline of 117 ± 86 to 34 ± 18 nmol/nmol (P = 0.004) at 48 wk and rose back to 53 ± 33 nmol/nmol (P = 0.003) 24 wk after withdrawal of treatment (P = 0.008 for trend of change over time). In the placebo group, N-telopeptide/creatinine ratio did not show significant change during the study. The difference in trend between the two groups was statistically significant (P = 0.039; Fig. 3Go). Twenty-four-hour urinary calcium was not significantly different between groups throughout the study (Fig. 3Go), although 24-h urinary calcium was significantly lower than baseline at 4 wk (P < 0.001), 12 wk (P = 0.003), and 24 wk (P = 0.015).

Adverse effects

At recruitment, a significant proportion of patients had musculoskeletal symptoms (60%), gastrointestinal symptoms (22.5%), and systemic symptoms (25%). However, no significant change in symptoms was recorded in either group throughout the study. There were 25 adverse events reported in the treatment group, and 24 were reported in the placebo group. Most were upper respiratory tract infections. There were two serious adverse events in the alendronate group. One patient was hospitalized because of dizziness and had a fall, another patient developed methyldopa-induced hemolytic anemia. There were three serious adverse events in the placebo group. One patient sustained a fractured right humerus after a fall. One developed first-degree heart block due to ß-blocker treatment. Another patient was excluded because of ibuprofen-induced gastric ulcer. All were withdrawn from the study. The number of adverse events was comparable between groups.


   Discussion
Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
References
 
To our knowledge, this is the second randomized, controlled trial in postmenopausal women with PHP to assess the medium-term efficacy of oral alendronate in protection against bone loss. We reported a progressive increase in BMD over 1 yr at the femoral neck and lumbar spine in postmenopausal women with PHP after alendronate. Compared with placebo, improvement in BMD (although to a lesser extent) remained evident 24 wk after withdrawal of treatment. Compared with the study by Rossini et al. (25), we not only confirmed the finding of improvement in BMD on alendronate treatment, but also showed that serum calcium was moderately reduced in the alendronate group, whereas PTH remain unchanged during the study. We have also demonstrated that the BMD increase is maintained at the hip but not at the spine after withdrawal of treatment. Further study is needed to determine whether maintenance therapy is necessary. Our findings suggest that alendronate is a useful alternative treatment for PHP in postmenopausal women.

The optimal management for PHP remains controversial. Surgical intervention has been shown to increase BMD especially at femoral neck and lumbar spine (26). This treatment modality may also lead to improvement in muscle strength and nonspecific symptoms (27). However, many patients with PHP are elderly, with other comorbidities rendering them at increased surgical risk. Currently, there are very limited data in the literature regarding the role of biphosphonates in elderly patients with PHP.

BMD has been shown to be a good predictor of future fracture (28), and alendronate has been shown to be an effective treatment for osteoporosis (14, 15). Fracture at the femoral neck has a large impact on quality of life, with deterioration of functional status even after successful surgery (29). In this context, given the generally osteoporotic bone profile in our PHP cohort, the T score at femoral neck in particular is low (at a mean of -3.15). This implies a theoretical risk of fracture at the femoral neck, and the increase in BMD at the femoral neck with alendronate treatment may be particularly important. Similarly, in our study, an increase in BMD was also detected at the lumbar spine. The lack of improvement in BMD at the distal radius indicates that alendronate does not have a major effect on this site. HRT has also been used to improve BMD in postmenopausal women with PHP, but compliance has generally been unsatisfactory in most surveys. The excellent compliance in our study suggests that alendronate may be a more suitable alternative than HRT in postmenopausal women with PHP.

One theoretical concern with the use of alendronate is a potential increase in PTH concentration in response to lowering of serum calcium (19, 20, 21), because hypercalcemia may exert a feedback suppression on PTH secretion in patients with PHP (30, 31). Short-term administration of pamidronate has been shown to result in an increase in PTH concentration (18). This may result in an increase in urinary calcium excretion and, hence, risk of renal calculi. Reassuringly, this study shows no difference in serum PTH concentration with placebo or alendronate after 48 wk. Furthermore, the urinary calcium excretion also did not change significantly with alendronate therapy.

In this study, serum calcium concentration did drop significantly with alendronate, albeit a small magnitude (-0.09 mmol/liter). Although there is insufficient evidence to support the use of alendronate for normalization of calcium in patients with PHP, it may have a role in stabilizing a modest degree of hypercalcemia. Interestingly, in our study, serum calcium levels rarely increased above 3.0 mmol/liter, an indication for surgery. In contrast, urinary calcium did not change throughout the study. Overall, alendronate should be considered safe and effective in postmenopausal women with PHP with only mild or modest hypercalcemia, at least over a 1-yr period.

In patients with PHP, bone (in particular cortical bone) is reduced by increased bone turnover. It has been shown that serum Bone-ALP, a marker of bone formation, is a predictor of improvement in BMD after parathyroidectomy (32). In this study, alendronate therapy produced a significant decrease in serum Bone-ALP and osteocalcin concentrations, both of which are indices of bone formation. Furthermore, the urinary N-telopeptide/creatinine ratio decreased significantly with alendronate, suggesting a decrease in bone resorptive activity. Short-term use of alendronate has also been shown to decrease other markers of bone resorption in PHP (33). Our study has clearly shown that this effect persists even with longer-term use. We have also demonstrated that the increase in BMD was mainly confined to the femoral neck and lumbar spine. This suggests that the main improvement associated with alendronate was in trabecular bone. The differential improvement at different sites is not well understood. One possible mechanism is that in PHP, the decrease in BMD observed in cortical bone is probably due to an increase in bone diameter rather than true osteoporosis (34). No comment can be made about fracture risk. However, an increase in fracture rate in PHP is not well documented (35, 36). Furthermore, our study was not sufficiently powered to study fracture incidence as a clinical endpoint. Whether oral alendronate given for a longer duration reduces fracture in postmenopausal women with PHP remains undetermined.

In conclusion, alendronate therapy improves BMD at the femoral neck and lumbar spine and has favorable effects on serum calcium concentration and markers of bone turnover in postmenopausal women with PHP over a 1-yr period. Hence, it may be a suitable alternative to surgery, especially in elderly patients who are at increased surgical risk. Its excellent tolerability enhances compliance, making it more superior to HRT in postmenopausal women with PHP. Whether its beneficial effects on bone persist beyond 1 yr requires further investigations.


   Acknowledgments
 
We are indebted to J. Woo, T. Kwok, M. Li, L. Lam, and A. Chong of the Department of Medicine and Therapeutics, Prince of Wales Hospital (Shatin, Hong Kong), for their help with the bone densitometry measurement.


   Footnotes
 
This study was supported in part by the Medical School Grant Program from Merck \|[amp ]\| Co., Inc.

Abbreviations: BMD, Bone mineral density; Bone-ALP, bone-specific alkaline phosphatase activity; CV, coefficient(s) of variation; HRT, hormone replacement therapy; PHP, primary hyperparathyroidism.

Received June 7, 2002.

Accepted October 17, 2002.


   References
Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 References
 

  1. Mundy GR, Cove DH, Fisken R 1980 Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet 1:1317–1320[Medline]
  2. Heath H, Hodgson SF, Kennedy MA 1980 Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med 302:189–193[Abstract]
  3. Mallette LE, Bilezikian JP, Heath DA, Aurbach GD 1974 Primary hyperparathyroidism: clinical and biochemical features. Medicine (Baltimore) 53:127–146[Medline]
  4. Silverberg SJ, Bilezikian JP 1996 Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 81:2036–2040[CrossRef][Medline]
  5. Ohrvall U, Akerstrom G, Ljunghall S, Lundgren E, Juhlin C, Rastad J 1994 Surgery for sporadic primary hyperparathyroidism in the elderly. World J Surg 18:612–618[CrossRef][Medline]
  6. Sosa JA, Powe NR, Levine MA, Udelsman R, Zeiger MA 1998 Profile of a clinical practice: thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons. J Clin Endocrinol Metab 83:2658–2665[Abstract/Free Full Text]
  7. Silverberg SJ, Shane E, de la Cruz L, Dempster DW, Feldman F, Seldin D, Jacobs TP, Siris ES, Cafferty M, Parisien MV 1989 Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 4:283–291[Medline]
  8. Delmas PD, Meunier PJ, Faysse E, Saubier EC 1986 Bone histomorphometry and serum bone gla-protein in the diagnosis of primary hyperparathyroidism. World J Surg 10:572–578[CrossRef][Medline]
  9. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RB, McMahon DJ, Bilezikian JP 1995 Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab 80:729–734[Abstract]
  10. Orr-Walker BJ, Evans MC, Clearwater JM, Horne A, Grey AB, Reid IR 2000 Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med 160:2161–2166[Abstract/Free Full Text]
  11. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR 1996 Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med 125:360–368[Abstract/Free Full Text]
  12. Hill DA, Weiss NS, LaCroix AZ 2000 Adherence to postmenopausal hormone therapy during the year after the initial prescription: a population-based study. Am J Obstet Gynecol 182:270–276[CrossRef][Medline]
  13. Rodan GA, Fleisch HA 1996 Bisphosphonates: mechanisms of action. J Clin Invest 97:2692–2696[Medline]
  14. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs Jr RW, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443[Abstract/Free Full Text]
  15. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541[CrossRef][Medline]
  16. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299[Abstract/Free Full Text]
  17. Jansson S, Tisell LE, Lindstedt G, Lundberg PA 1991 Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. Surgery 110:480–486[Medline]
  18. Adami S, Mian M, Bertoldo F, Rossini M, Jayawerra P, O’Riordan JL, Lo Cascio V 1990 Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: effects of bisphosphonate treatment. Clin Endocrinol (Oxf) 33:391–397[Medline]
  19. Kaplan RA, Geho WB, Poindexter C, Haussler M, Dietz GW, Pak CY 1977 Metabolic effects of diphosphonate in primary hyperparathyroidism. J Clin Pharmacol 17:410–419[Abstract]
  20. Shane E, Baquiran DC, Bilezikian JP 1981 Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Ann Intern Med 95:23–27
  21. Reasner CA, Stone MD, Hosking DJ, Ballah A, Mundy GR 1993 Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 77:1067–1071[Abstract]
  22. 1991 NIH conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Ann Intern Med 114:593–597
  23. Payne RB, Little AJ, Williams RB, Milner JR 1973 Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 4:643–646
  24. Winer BJ, Brown DR, Michels KM 1991 Statistical principles in experimental design, 3rd Ed. New York: McGraw-Hill
  25. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S 2001 Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 16:113–119[CrossRef][Medline]
  26. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP 1999 A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249–1255[Abstract/Free Full Text]
  27. Chan AK, Duh QY, Katz MH, Siperstein AE, Clark OH 1995 Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study. Ann Surg 222:402–412; discussion, 412–414[Medline]
  28. Marshall D, Johnell O, Wedel H 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259[Abstract/Free Full Text]
  29. Magaziner J, Simonsick EM, Kashner TM, Hebel JR, Kenzora JE 1990 Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study. J Gerontol 45:M101—M107
  30. Brown EM, Broadus AE, Brennan MF, Gardner DG, Marx SJ, Spiegel AM, Downs Jr RW, Attie M, Aurbach GD 1979 Direct comparison in vivo and in vitro of suppressibility of parathyroid function by calcium in primary hyperparathyroidism. J Clin Endocrinol Metab 48:604–610[Medline]
  31. Gardin JP, Patron P, Fouqueray B, Prigent A, Paillard M 1988 Maximal PTH secretory rate and set point for calcium in normal subjects and patients with primary hyperparathyroidism. In vivo studies. Miner Electrolyte Metab 14:221–228[Medline]
  32. Nakaoka D, Sugimoto T, Kobayashi T, Yamaguchi T, Kobayashi A, Chihara K 2000 Prediction of bone mass change after parathyroidectomy in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 85:1901–1907[Abstract/Free Full Text]
  33. LoCascio V, Braga V, Bertoldo F, Bettica P, Pasini AF, Stefani L, Moro L 1994 Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism. Clin Endocrinol (Oxf) 41:47–51[Medline]
  34. Adami S, Braga V, Squaranti R, Rossini M, Gatti D, Zamberlan N 1998 Bone measurements in asymptomatic primary hyperparathyroidism. Bone 22:565–570[Medline]
  35. Khosla S, Melton 3rd LJ, Wermers RA, Crowson CS, O’Fallon W, Riggs B 1999 Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 14:1700–1707[CrossRef][Medline]
  36. Larsson K, Ljunghall S, Krusemo UB, Naessen T, Lindh E, Persson I 1993 The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years. J Intern Med 234:585–593[Medline]



This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
E. Ambrogini, F. Cetani, L. Cianferotti, E. Vignali, C. Banti, G. Viccica, A. Oppo, P. Miccoli, P. Berti, J. P. Bilezikian, et al.
Surgery or Surveillance for Mild Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Clinical Trial
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3114 - 3121.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
G. J. Strewler
A 64-Year-Old Woman With Primary Hyperparathyroidism
JAMA, April 13, 2005; 293(14): 1772 - 1779.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Peacock, J. P. Bilezikian, P. S. Klassen, M. D. Guo, S. A. Turner, and D. Shoback
Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary Hyperparathyroidism
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 135 - 141.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. A. Khan, J. P. Bilezikian, A. W. C. Kung, M. M. Ahmed, S. J. Dubois, A. Y. Y. Ho, D. Schussheim, M. R. Rubin, A. M. Shaikh, S. J. Silverberg, et al.
Alendronate in Primary Hyperparathyroidism: A Double-Blind, Randomized, Placebo-Controlled Trial
J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3319 - 3325.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. P. Bilezikian and S. J. Silverberg
Asymptomatic Primary Hyperparathyroidism
N. Engl. J. Med., April 22, 2004; 350(17): 1746 - 1751.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chow, C. C.
Right arrow Articles by Cockram, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chow, C. C.
Right arrow Articles by Cockram, C. S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals